NICE Rejects Avastin-Xeloda As Combination Therapy For Breast Cancer

News: The UK's National Institute for Health and Clinical Excellence (NICE) has rejected Avastin (bevacizumab) as the first-line treatment for breast cancer in combination with Xeloda (capecitabine). NICE said Avastin failed to provide enough patient benefit to justify its cost and recommended the National Health Service did not reimburse the drug. Avastin's use to treat breast cancer came into question in 2011 when it was suggested the medication posed more risks than benefits to patients. Avastin, manufactured by Roche, was rejected by NICE in 2011 for treating metastatic breast cancer in combination with paclitaxel. The US Food and Drug Administration also rejected the drug for the same indication in November 2011.

BMI View: BMI's Burden of Disease Database estimates that the number of disability-adjusted life years (DALYs) lost to breast cancer in the UK was 154,892 in 2010. We forecast this will decrease by 0.30% to 154,433 DALYs by 2015 and by 5.15% to 146,479 DALYs by 2030.

Access all of our latest analysis, data and forecasts - request a trial